{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:00:11Z","timestamp":1789747211526,"version":"4.0.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23ZR1448200"],"award-info":[{"award-number":["23ZR1448200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67533-7","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:01:46Z","timestamp":1768384906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-4701","authenticated-orcid":false,"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5532-3454","authenticated-orcid":false,"given":"Yingrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6803-7438","authenticated-orcid":false,"given":"Xiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-5437","authenticated-orcid":false,"given":"Zelin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8028-8483","authenticated-orcid":false,"given":"Jiaxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3155-2847","authenticated-orcid":false,"given":"Haixia","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenkai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-8433","authenticated-orcid":false,"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-744X","authenticated-orcid":false,"given":"Yijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-4496","authenticated-orcid":false,"given":"Chuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0429-0802","authenticated-orcid":false,"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-648X","authenticated-orcid":false,"given":"Yaoting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9668-7756","authenticated-orcid":false,"given":"Zhiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3869-7651","authenticated-orcid":false,"given":"Tiannan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"67533_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells Jr.","year":"2015","unstructured":"Wells, S. A. Jr. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567\u2013610 (2015).","journal-title":"Thyroid"},{"key":"67533_CR2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim, H., Devesa, S. S., Sosa, J. A., Check, D. & Kitahara, C. M. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 317, 1338\u20131348 (2017).","journal-title":"JAMA"},{"key":"67533_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1089\/thy.2019.0415","volume":"30","author":"M Pereira","year":"2020","unstructured":"Pereira, M., Williams, V. L., Hallanger Johnson, J. & Valderrabano, P. Thyroid cancer incidence trends in the United States: association with changes in professional guideline recommendations. Thyroid 30, 1132\u20131140 (2020).","journal-title":"Thyroid"},{"key":"67533_CR4","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.22244","volume":"107","author":"S Roman","year":"2006","unstructured":"Roman, S., Lin, R. & Sosa, J. A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107, 2134\u20132142 (2006).","journal-title":"Cancer"},{"key":"67533_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.6004\/jnccn.2010.0042","volume":"8","author":"JF Moley","year":"2010","unstructured":"Moley, J. F. Medullary thyroid carcinoma: management of lymph node metastases. J. Natl. Compr. Cancer Netw. 8, 549\u2013556 (2010).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"67533_CR6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/00000658-199906000-00016","volume":"229","author":"JF Moley","year":"1999","unstructured":"Moley, J. F. & DeBenedetti, M. K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann. Surg. 229, 880\u2013887 (1999).","journal-title":"Ann. Surg."},{"key":"67533_CR7","doi-asserted-by":"publisher","first-page":"204201882110496","DOI":"10.1177\/20420188211049611","volume":"12","author":"MA Bartz-Kurycki","year":"2021","unstructured":"Bartz-Kurycki, M. A., Oluwo, O. E. & Morris-Wiseman, L. F. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis. Ther. Adv. Endocrinol. Metab. 12, 20420188211049611 (2021).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"67533_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamasurg.2017.3555","volume":"153","author":"EJ Kuo","year":"2018","unstructured":"Kuo, E. J. et al. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg. 153, 52\u201359 (2018).","journal-title":"JAMA Surg."},{"key":"67533_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12022-023-09753-5","volume":"34","author":"CK Jung","year":"2023","unstructured":"Jung, C. K. et al. Update on C-cell neuroendocrine neoplasm: prognostic and predictive histopathologic and molecular features of medullary thyroid carcinoma. Endocr. Pathol. 34, 1\u201322 (2023).","journal-title":"Endocr. Pathol."},{"key":"67533_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/thy.2020.0167","volume":"31","author":"A Kotwal","year":"2021","unstructured":"Kotwal, A., Erickson, D., Geske, J. R., Hay, I. D. & Castro, M. R. Predicting outcomes in sporadic and hereditary medullary thyroid carcinoma over two decades. Thyroid 31, 616\u2013626 (2021).","journal-title":"Thyroid"},{"key":"67533_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/thy.2023.0279","volume":"34","author":"B Xu","year":"2024","unstructured":"Xu, B. et al. Association of the genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study. Thyroid 34, 167\u2013176 (2024).","journal-title":"Thyroid"},{"key":"67533_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1200\/JCO.21.01329","volume":"40","author":"B Xu","year":"2022","unstructured":"Xu, B. et al. International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma. J. Clin. Oncol. 40, 96\u2013104 (2022).","journal-title":"J. Clin. Oncol."},{"key":"67533_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2023.0482","volume":"34","author":"S Censi","year":"2024","unstructured":"Censi, S. et al. Tumor grade and molecular characteristics associated with survival in sporadic medullary thyroid carcinoma. Thyroid 34, 177\u2013185 (2024).","journal-title":"Thyroid"},{"key":"67533_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12022-024-09817-0","volume":"35","author":"I Ruz-Caracuel","year":"2024","unstructured":"Ruz-Caracuel, I. et al. Transcriptomic differences in medullary thyroid carcinoma according to grade. Endocr. Pathol. 35, 207\u2013218 (2024).","journal-title":"Endocr. Pathol."},{"key":"67533_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s12022-022-09719-z","volume":"33","author":"E Vissio","year":"2022","unstructured":"Vissio, E. et al. External validation of three available grading systems for medullary thyroid carcinoma in a single institution cohort. Endocr. Pathol. 33, 359\u2013370 (2022).","journal-title":"Endocr. Pathol."},{"key":"67533_CR16","first-page":"1193","volume":"32","author":"A Nigam","year":"2022","unstructured":"Nigam, A. et al. Tumor grade predicts for calcitonin doubling times and disease-specific outcomes after resection of medullary thyroid carcinoma. Thyroid 32, 1193\u20131200 (2022).","journal-title":"Thyroid"},{"key":"67533_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","volume":"20","author":"R Ciampi","year":"2019","unstructured":"Ciampi, R. et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 20, 324\u2013336 (2019).","journal-title":"iScience"},{"key":"67533_CR18","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1158\/1078-0432.CCR-11-0242","volume":"17","author":"D Abraham","year":"2011","unstructured":"Abraham, D. et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin. Cancer Res. 17, 4772\u20134781 (2011).","journal-title":"Clin. Cancer Res."},{"key":"67533_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-025-08584-0","volume":"638","author":"T Guo","year":"2025","unstructured":"Guo, T. J. A. S. a. M. M. Mass-spectrometry-based proteomics: from single cells to clinical applications. nature 638, 901\u2013911 (2025).","journal-title":"nature"},{"key":"67533_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1634\/theoncologist.2017-0399","volume":"23","author":"S Zhan","year":"2018","unstructured":"Zhan, S., Li, J., Wang, T. & Ge, W. Quantitative proteomics analysis of sporadic medullary thyroid cancer reveals FN1 as a potential novel candidate prognostic biomarker. Oncologist 23, 1415\u20131425 (2018).","journal-title":"Oncologist"},{"key":"67533_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41421-022-00479-y","volume":"8","author":"X Shi","year":"2022","unstructured":"Shi, X. et al. Integrated proteogenomic characterization of medullary thyroid carcinoma. Cell Discov. 8, 120 (2022).","journal-title":"Cell Discov."},{"key":"67533_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","volume":"28","author":"RB Damgaard","year":"2021","unstructured":"Damgaard, R. B. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 28, 423\u2013426 (2021).","journal-title":"Cell Death Differ."},{"key":"67533_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1152\/physrev.00027.2001","volume":"82","author":"MH Glickman","year":"2002","unstructured":"Glickman, M. H. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373\u2013428 (2002).","journal-title":"Physiol. Rev."},{"key":"67533_CR24","doi-asserted-by":"publisher","first-page":"e34032","DOI":"10.1016\/j.heliyon.2024.e34032","volume":"10","author":"X Xiong","year":"2024","unstructured":"Xiong, X. et al. Ubiquitin-modifying enzymes in thyroid cancer: mechanisms and functions. Heliyon 10, e34032 (2024).","journal-title":"Heliyon"},{"key":"67533_CR25","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1242\/jcs.203885","volume":"130","author":"BD Hyndman","year":"2017","unstructured":"Hyndman, B. D. et al. Differential recruitment of E3 ubiquitin ligase complexes regulates RET isoform internalization. J. Cell Sci. 130, 3282\u20133296 (2017).","journal-title":"J. Cell Sci."},{"key":"67533_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1210\/endo.141.1.7265","volume":"141","author":"T Dilla","year":"2000","unstructured":"Dilla, T., Velasco, J. A., Medina, D. L., Gonzalez-Palacios, J. F. & Santisteban, P. The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells. Endocrinology 141, 420\u2013429 (2000).","journal-title":"Endocrinology"},{"key":"67533_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ejca.2003.11.016","volume":"40","author":"T Takano","year":"2004","unstructured":"Takano, T. et al. PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. Eur. J. Cancer 40, 614\u2013618 (2004).","journal-title":"Eur. J. Cancer"},{"key":"67533_CR28","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/nprot.2013.120","volume":"8","author":"ND Udeshi","year":"2013","unstructured":"Udeshi, N. D., Mertins, P., Svinkina, T. & Carr, S. A. Large-scale identification of ubiquitination sites by mass spectrometry. Nat. Protoc. 8, 1950\u20131960 (2013).","journal-title":"Nat. Protoc."},{"key":"67533_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.molcel.2011.08.025","volume":"44","author":"W Kim","year":"2011","unstructured":"Kim, W. et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44, 325\u2013340 (2011).","journal-title":"Mol. Cell"},{"key":"67533_CR30","doi-asserted-by":"publisher","first-page":"M111 013284","DOI":"10.1074\/mcp.M111.013284","volume":"10","author":"SA Wagner","year":"2011","unstructured":"Wagner, S. A. et al. A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol. Cell Proteom. 10, M111 013284 (2011).","journal-title":"Mol. Cell Proteom."},{"key":"67533_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1145926","volume":"14","author":"G Fanciulli","year":"2023","unstructured":"Fanciulli, G. et al. Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?. Front. Endocrinol. 14, 1145926 (2023).","journal-title":"Front. Endocrinol."},{"key":"67533_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nm.3807","volume":"21","author":"T Guo","year":"2015","unstructured":"Guo, T. et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat. Med. 21, 407\u2013413 (2015).","journal-title":"Nat. Med."},{"key":"67533_CR33","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1038\/s41596-022-00727-1","volume":"17","author":"X Cai","year":"2022","unstructured":"Cai, X. et al. High-throughput proteomic sample preparation using pressure cycling technology. Nat. Protoc. 17, 2307\u20132325 (2022).","journal-title":"Nat. Protoc."},{"key":"67533_CR34","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41592-020-00998-0","volume":"17","author":"F Meier","year":"2020","unstructured":"Meier, F. et al. diaPASEF: parallel accumulation-serial fragmentation combined with data-independent acquisition. Nat. Methods 17, 1229\u20131236 (2020).","journal-title":"Nat. Methods"},{"key":"67533_CR35","doi-asserted-by":"crossref","unstructured":"Mule, C. et al. Higher RET gene expression levels do not represent an alternative RET activation mechanism in medullary thyroid carcinoma. Biomolecules 11, 1542 (2021).","DOI":"10.3390\/biom11101542"},{"key":"67533_CR36","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1089\/thy.2020.0290","volume":"31","author":"IJ Marques","year":"2021","unstructured":"Marques, I. J. et al. Identification of SPRY4 as a novel candidate susceptibility gene for familial nonmedullary thyroid cancer. Thyroid 31, 1366\u20131375 (2021).","journal-title":"Thyroid"},{"key":"67533_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15955-w","volume":"11","author":"A Krishnan","year":"2020","unstructured":"Krishnan, A. et al. Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas. Nat. Commun. 11, 2056 (2020).","journal-title":"Nat. Commun."},{"key":"67533_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01665-y","volume":"21","author":"E Renaud","year":"2022","unstructured":"Renaud, E. et al. Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCdelta for tumorigenesis. Mol. Cancer 21, 195 (2022).","journal-title":"Mol. Cancer"},{"key":"67533_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2016.39","volume":"26","author":"KN Swatek","year":"2016","unstructured":"Swatek, K. N. & Komander, D. Ubiquitin modifications. Cell Res 26, 399\u2013422 (2016).","journal-title":"Cell Res"},{"key":"67533_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.cell.2014.03.037","volume":"157","author":"HJ Meyer","year":"2014","unstructured":"Meyer, H. J. & Rape, M. Enhanced protein degradation by branched ubiquitin chains. Cell 157, 910\u2013921 (2014).","journal-title":"Cell"},{"key":"67533_CR41","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.tcb.2019.06.003","volume":"29","author":"DL Haakonsen","year":"2019","unstructured":"Haakonsen, D. L. & Rape, M. Branching out: improved signaling by heterotypic ubiquitin chains. Trends Cell Biol. 29, 704\u2013716 (2019).","journal-title":"Trends Cell Biol."},{"key":"67533_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45558-8","volume":"15","author":"EM Wenzel","year":"2024","unstructured":"Wenzel, E. M. et al. Intercellular transfer of cancer cell invasiveness via endosome-mediated protease shedding. Nat. Commun. 15, 1277 (2024).","journal-title":"Nat. Commun."},{"key":"67533_CR43","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564\u20131579 (2023).","journal-title":"Cell"},{"key":"67533_CR44","doi-asserted-by":"publisher","first-page":"1 30 31","DOI":"10.1002\/cpbi.5","volume":"54","author":"G Stelzer","year":"2016","unstructured":"Stelzer, G. et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinforma. 54, 1 30 31\u201331 30 33 (2016).","journal-title":"Curr. Protoc. Bioinforma."},{"key":"67533_CR45","doi-asserted-by":"publisher","first-page":"D609","DOI":"10.1093\/nar\/gkae1010","volume":"53","author":"C UniProt","year":"2025","unstructured":"UniProt, C. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Res. 53, D609\u2013D617 (2025).","journal-title":"Nucleic Acids Res."},{"key":"67533_CR46","doi-asserted-by":"publisher","first-page":"D719","DOI":"10.1093\/nar\/gkab962","volume":"50","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase\/deubiquitinase-substrate interactions in eukaryotic species. Nucleic Acids Res. 50, D719\u2013D728 (2022).","journal-title":"Nucleic Acids Res."},{"key":"67533_CR47","doi-asserted-by":"crossref","unstructured":"Szklarczyk, D. et al. The STRING database in 2025: protein networks with directionality of regulation. Nucleic Acids Res. 53, D730\u2013D737 (2024).","DOI":"10.1093\/nar\/gkae1113"},{"key":"67533_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"67533_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."},{"key":"67533_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/00313029400169341","volume":"26","author":"G Barresi","year":"1994","unstructured":"Barresi, G. & Tuccari, G. Immunocytochemical demonstration of melanotransferrin (p97) in thyroid tumors of follicular cell origin. Pathology 26, 127\u2013129 (1994).","journal-title":"Pathology"},{"key":"67533_CR51","doi-asserted-by":"publisher","first-page":"26354","DOI":"10.1074\/jbc.M701665200","volume":"282","author":"H Yamaguchi","year":"2007","unstructured":"Yamaguchi, H. et al. Peptidomic identification and biological validation of neuroendocrine regulatory peptide-1 and -2. J. Biol. Chem. 282, 26354\u201326360 (2007).","journal-title":"J. Biol. Chem."},{"key":"67533_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-25","volume":"8","author":"A Hamm","year":"2008","unstructured":"Hamm, A. et al. Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 8, 25 (2008).","journal-title":"BMC Cancer"},{"key":"67533_CR53","doi-asserted-by":"publisher","first-page":"11096","DOI":"10.18632\/aging.202765","volume":"13","author":"QH Chang","year":"2021","unstructured":"Chang, Q. H. et al. Pan-cancer analysis identifies ITIH1 as a novel prognostic indicator for hepatocellular carcinoma. Aging 13, 11096\u201311119 (2021).","journal-title":"Aging"},{"key":"67533_CR54","doi-asserted-by":"crossref","unstructured":"Kopylov, A. T. et al. Revelation of proteomic indicators for colorectal cancer in initial stages of development. Molecules 25, 619 (2020).","DOI":"10.3390\/molecules25030619"},{"key":"67533_CR55","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.2174\/0929867330666230427102920","volume":"31","author":"W Jiang","year":"2024","unstructured":"Jiang, W. et al. PAFAH1B3 regulates papillary thyroid carcinoma cell proliferation and metastasis by affecting the EMT. Curr. Med. Chem. 31, 1152\u20131164 (2024).","journal-title":"Curr. Med. Chem."},{"key":"67533_CR56","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)61452-9","volume":"379","author":"MP Rayman","year":"2012","unstructured":"Rayman, M. P. Selenium and human health. Lancet 379, 1256\u20131268 (2012).","journal-title":"Lancet"},{"key":"67533_CR57","doi-asserted-by":"publisher","first-page":"14912","DOI":"10.1073\/pnas.1310894110","volume":"110","author":"DI Benjamin","year":"2013","unstructured":"Benjamin, D. I. et al. Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc. Natl. Acad. Sci. USA 110, 14912\u201314917 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67533_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37924-9","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. Nat. Commun. 14, 2194 (2023).","journal-title":"Nat. Commun."},{"key":"67533_CR59","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1128\/MCB.02006-05","volume":"26","author":"L Bockstaele","year":"2006","unstructured":"Bockstaele, L. et al. Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK \u201cinhibitors. Mol. Cell Biol. 26, 5070\u20135085 (2006).","journal-title":"Mol. Cell Biol."},{"key":"67533_CR60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/thy.2016.0285","volume":"27","author":"P Weinberger","year":"2017","unstructured":"Weinberger, P. et al. Cell cycle M-phase genes are highly upregulated in anaplastic thyroid carcinoma. Thyroid 27, 236\u2013252 (2017).","journal-title":"Thyroid"},{"key":"67533_CR61","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/his.13778","volume":"74","author":"J Wu","year":"2019","unstructured":"Wu, J. et al. Expression of epithelial-mesenchymal transition regulators TWIST, SLUG and SNAIL in follicular thyroid tumours may relate to widely invasive, poorly differentiated and distant metastasis. Histopathology 74, 780\u2013791 (2019).","journal-title":"Histopathology"},{"key":"67533_CR62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/1097-0142(19940701)74:1<134::AID-CNCR2820740122>3.0.CO;2-M","volume":"74","author":"M Roncalli","year":"1994","unstructured":"Roncalli, M. et al. Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. Cancer 74, 134\u2013141 (1994).","journal-title":"Cancer"},{"key":"67533_CR63","doi-asserted-by":"publisher","first-page":"100244","DOI":"10.1016\/j.modpat.2023.100244","volume":"36","author":"F Torricelli","year":"2023","unstructured":"Torricelli, F. et al. Medullary thyroid carcinomas classified according to the international medullary carcinoma grading system and a Surveillance, Epidemiology, and End Results-based metastatic risk score: a correlation with genetic profile and angioinvasion. Mod. Pathol. 36, 100244 (2023).","journal-title":"Mod. Pathol."},{"key":"67533_CR64","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s12020-024-03958-2","volume":"86","author":"B Liu","year":"2024","unstructured":"Liu, B., Peng, Y., Su, Y., Diao, C. & Cheng, R. Treatment and management of medullary thyroid microcarcinoma: a 10-year retrospective study from a single center. Endocrine 86, 1081\u20131089 (2024).","journal-title":"Endocrine"},{"key":"67533_CR65","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12022-012-9225-8","volume":"23","author":"BM Erovic","year":"2012","unstructured":"Erovic, B. M. et al. Prognostic and predictive markers in medullary thyroid carcinoma. Endocr. Pathol. 23, 232\u2013242 (2012).","journal-title":"Endocr. Pathol."},{"key":"67533_CR66","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1245\/s10434-010-1021-4","volume":"17","author":"A Rios","year":"2010","unstructured":"Rios, A. et al. Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma. Ann. Surg. Oncol. 17, 2444\u20132451 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"67533_CR67","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.bjc.6600930","volume":"88","author":"G Pellegriti","year":"2003","unstructured":"Pellegriti, G. et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br. J. Cancer 88, 1537\u20131542 (2003).","journal-title":"Br. J. Cancer"},{"key":"67533_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopha.2004.05.001","volume":"58","author":"K Kameyama","year":"2004","unstructured":"Kameyama, K., Okinaga, H. & Takami, H. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed. Pharmacother. 58, 345\u2013347 (2004).","journal-title":"Biomed. Pharmacother."},{"key":"67533_CR69","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.surg.2018.03.018","volume":"164","author":"KY Jung","year":"2018","unstructured":"Jung, K. Y. et al. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea. Surgery 164, 312\u2013318 (2018).","journal-title":"Surgery"},{"key":"67533_CR70","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1089\/1050725042451220","volume":"14","author":"YJ Chung","year":"2004","unstructured":"Chung, Y. J. et al. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A. Thyroid 14, 813\u2013818 (2004).","journal-title":"Thyroid"},{"key":"67533_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10689-015-9828-6","volume":"15","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives. Fam. Cancer 15, 99\u2013104 (2016).","journal-title":"Fam. Cancer"},{"key":"67533_CR72","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1089\/thy.2012.0134","volume":"22","author":"XP Qi","year":"2012","unstructured":"Qi, X. P. et al. RET proto-oncogene genetic screening of families with multiple endocrine neoplasia type 2 optimizes diagnostic and clinical management in China. Thyroid 22, 1257\u20131265 (2012).","journal-title":"Thyroid"},{"key":"67533_CR73","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1365-2265.2007.02927.x","volume":"67","author":"Y Zhou","year":"2007","unstructured":"Zhou, Y. et al. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B. Clin. Endocrinol. 67, 570\u2013576 (2007).","journal-title":"Clin. Endocrinol."},{"key":"67533_CR74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.21147\/j.issn.1000-9604.2017.03.08","volume":"29","author":"X Zhang","year":"2017","unstructured":"Zhang, X. et al. Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? A single-center study. Chin. J. Cancer Res 29, 223\u2013230 (2017).","journal-title":"Chin. J. Cancer Res"},{"key":"67533_CR75","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ccr.2012.10.024","volume":"22","author":"H Hu","year":"2012","unstructured":"Hu, H. et al. CRL4B catalyzes H2AK119 monoubiquitination and coordinates with PRC2 to promote tumorigenesis. Cancer Cell 22, 781\u2013795 (2012).","journal-title":"Cancer Cell"},{"key":"67533_CR76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40164-017-0077-2","volume":"6","author":"Y Li","year":"2017","unstructured":"Li, Y. & Wang, X. The role of cullin4B in human cancers. Exp. Hematol. Oncol. 6, 17 (2017).","journal-title":"Exp. Hematol. Oncol."},{"key":"67533_CR77","doi-asserted-by":"publisher","first-page":"102389","DOI":"10.1016\/j.tranon.2025.102389","volume":"56","author":"H Gu","year":"2025","unstructured":"Gu, H. et al. CUL4B regulates thyroid cancer differentiation and treatment sensitivity by ubiquitinating ARID1A. Transl. Oncol. 56, 102389 (2025).","journal-title":"Transl. Oncol."},{"key":"67533_CR78","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/cdd.2014.121","volume":"21","author":"J Liu","year":"2014","unstructured":"Liu, J. et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ. 21, 1792\u20131804 (2014).","journal-title":"Cell Death Differ."},{"key":"67533_CR79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40164-022-00322-w","volume":"11","author":"N Huang","year":"2022","unstructured":"Huang, N. et al. TRIM family contribute to tumorigenesis, cancer development, and drug resistance. Exp. Hematol. Oncol. 11, 75 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"67533_CR80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-023-02764-4","volume":"42","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q. et al. TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination. J. Exp. Clin. Cancer Res. 42, 195 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"67533_CR81","doi-asserted-by":"crossref","unstructured":"Xu, J. et al. TRIM32 promotes anoikis resistance and metastasis in NSCLC by degrading CHEK2 to enhance IL-6 secretion. Cell Death Differ. (2025).","DOI":"10.1038\/s41418-025-01559-8"},{"key":"67533_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49824-7","volume":"15","author":"Y Hou","year":"2024","unstructured":"Hou, Y. et al. The neurotransmitter calcitonin gene-related peptide shapes an immunosuppressive microenvironment in medullary thyroid cancer. Nat. Commun. 15, 5555 (2024).","journal-title":"Nat. Commun."},{"key":"67533_CR83","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","volume":"4","author":"K Flem-Karlsen","year":"2018","unstructured":"Flem-Karlsen, K., Fodstad, O., Tan, M. & Nunes-Xavier, C. E. B7-H3 in cancer - beyond immune regulation. Trends Cancer 4, 401\u2013404 (2018).","journal-title":"Trends Cancer"},{"key":"67533_CR84","doi-asserted-by":"crossref","unstructured":"Hincza-Nowak, K. et al. CD276 as a candidate target for immunotherapy in medullary thyroid cancer. Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms241210019"},{"key":"67533_CR85","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/1878-0261.12570","volume":"13","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. Mol. Oncol. 13, 2305\u20132328 (2019).","journal-title":"Mol. Oncol."},{"key":"67533_CR86","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"67533_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31492-0","volume":"13","author":"V Demichev","year":"2022","unstructured":"Demichev, V. et al. dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts. Nat. Commun. 13, 3944 (2022).","journal-title":"Nat. Commun."},{"key":"67533_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-04322-9","volume":"11","author":"L Li","year":"2024","unstructured":"Li, L. et al. Comprehensive mass spectral libraries of human thyroid tissues and cells. Sci. Data 11, 1448 (2024).","journal-title":"Sci. Data"},{"key":"67533_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25454-1","volume":"12","author":"M Steger","year":"2021","unstructured":"Steger, M. et al. Time-resolved in vivo ubiquitinome profiling by DIA-MS reveals USP7 targets on a proteome-wide scale. Nat. Commun. 12, 5399 (2021).","journal-title":"Nat. Commun."},{"key":"67533_CR90","doi-asserted-by":"publisher","first-page":"e1005973","DOI":"10.1371\/journal.pcbi.1005973","volume":"14","author":"R Wei","year":"2018","unstructured":"Wei, R. et al. GSimp: A Gibbs sampler based left-censored missing value imputation approach for metabolomics studies. PLoS Comput Biol. 14, e1005973 (2018).","journal-title":"PLoS Comput Biol."},{"key":"67533_CR91","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1093\/nar\/gkaa498","volume":"48","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. NAguideR: performing and prioritizing missing value imputations for consistent bottom-up proteomic analyses. Nucleic Acids Res 48, e83 (2020).","journal-title":"Nucleic Acids Res"},{"key":"67533_CR92","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"67533_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-11-367","volume":"11","author":"R Gaujoux","year":"2010","unstructured":"Gaujoux, R. & Seoighe, C. A flexible R package for nonnegative matrix factorization. BMC Bioinforma. 11, 367 (2010).","journal-title":"BMC Bioinforma."},{"key":"67533_CR94","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"67533_CR95","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ni.3693","volume":"18","author":"JC Rieckmann","year":"2017","unstructured":"Rieckmann, J. C. et al. Social network architecture of human immune cells unveiled by quantitative proteomics. Nat. Immunol. 18, 583\u2013593 (2017).","journal-title":"Nat. Immunol."},{"key":"67533_CR96","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-022-00442-x","volume":"8","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Artificial intelligence defines protein-based classification of thyroid nodules. Cell Discov. 8, 85 (2022).","journal-title":"Cell Discov."},{"key":"67533_CR97","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1109\/TVCG.2022.3223399","volume":"30","author":"Z Zang","year":"2024","unstructured":"Zang, Z. et al. DMT-EV: an explainable deep network for dimension reduction. IEEE Trans. Vis. Comput. Graph 30, 1710\u20131727 (2024).","journal-title":"IEEE Trans. Vis. Comput. Graph"},{"key":"67533_CR98","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"67533_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"67533_CR100","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67533_CR101","doi-asserted-by":"publisher","first-page":"D1539","DOI":"10.1093\/nar\/gkac1040","volume":"51","author":"EW Deutsch","year":"2023","unstructured":"Deutsch, E. W. et al. The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res. 51, D1539\u2013D1548 (2023).","journal-title":"Nucleic Acids Res."},{"key":"67533_CR102","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkae1011","volume":"53","author":"Y Perez-Riverol","year":"2025","unstructured":"Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543\u2013D553 (2025).","journal-title":"Nucleic Acids Res."},{"key":"67533_CR103","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211\u2013D1217 (2019).","journal-title":"Nucleic Acids Res."},{"key":"67533_CR104","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen, T. et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 50, D1522\u2013D1527 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67533-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67533-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:47:01Z","timestamp":1768474021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67533-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67533"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67533-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.G. and Y.Z. are shareholders of Westlake Omics (Hangzhou) Biotechnology Co., Ltd. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}